Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
A half dozen digital health startups went head to head this weekend in a pitch contest hosted by the American Heart Association.
The competition’s cohort ranged from well-known heavy hitters like Welldoc to Korean hospital spinout Vuno, but in the end it was Pittsburgh-based Forest Devices that claimed top honors from both the contest’s eight judges and its audience.
“Our solution is AlphaSTROKE...
Type 1 diabetes management and CGM integration are now on the table for WellDoc’s BlueStar, a management platform well known for being the first mobile health product to secure reimbursement as a diabetes therapy.
Thanks to a new FDA clearance, the company’s seventh, BlueStar will include integrated glucose level insights related to food, medication and activity that are based on the data from...
Remote monitoring data management firm Validic has partnered with digital chronic disease management company WellDoc to help BlueStar users connect their wearables, apps and other home health monitoring devices to the platform. According to the companies, the integration will allow for more streamlined aggregation of users’ health data and more precise digital coaching.
"Today's healthcare...
On-demand behavioral health platform Ginger.io has named Russell Glass as its next CEO. Before taking the job at Ginger.io, Glass was the CEO of a B2B marketing company called Bizo. Glass’ start date is set for Sept. 10.
“As I evaluated my next venture, I wanted to create a positive impact on people’s lives,” Glass said in a statement. “Ginger.io is a perfect fit — a phenomenal team of people...
WellDoc has expanded its BlueStar digital diabetes management platform to include a weight loss feature and a feature for those with both diabetes and hypertension. A standalone product for hypertension is also coming from the company later this year.
“The American Diabetes Association reports that nearly one in three American adults has hypertension, and two in three people with diabetes have...
The NHS is looking to ramp up its patient data security, after signing a contract with software company Privitar for its de-identification technology. The new technology will help prevent a person’s identify from being connected to their information.
“The health and care landscape is rapidly changing, and we can improve individual patient care if our systems can deliver a complete picture of...
Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018.
“Looking at some of the metrics that Sempre has been able to provide...
Samsung Health users will now have access to a new consumer-grade version of WellDoc’s digital diabetes management platform, the two companies announced this morning.
The Diabetes Wellness Program is a 12-week wellness program designed to help Type 2 diabetes patients improve unhealthy behaviors and better manage their condition. The program is available through the Samsung Health version 5.14 or...
WellDoc’s digital diabetes management therapeutic BlueStar will now be available on the Solera network as a diabetes management option.
Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the...
